Live event feed: Dr Alex Kudrin

world vaccine congress lyon, cancer vaccine development, FDA

Dr Alex Kudrin has graduated Orenburg Medical Academy in Russia in 1997 and received PhD / MD in Respiratory Medicine and Immunology from Moscow Medical University (2001) and MBA from Westminster University in London (2011). He was employed at Acambis, GlaxoSmithKline and GlaxoSmithKline Biologicals at various senior positions in clinical development of novel anti-inflammatory agents and vaccines. Between 2007-2011, he was appointed as a Medical Assessor in Biological PLAT of Licensing Division at MHRA in London participating in clinical evaluation, scientific advice and approval of various biotechnology products, including monoclonal antibodies, vaccines, blood products, and advanced cell therapies. Currently he holds position of a Medical Director in Gastroenterology, Immunology and Vaccines at Takeda Global R&D in London. Dr Kudrin has specific interests in oncology, immunology, vaccines; clinical development, emerging markets in Asia and Russia. He is an author of 50 publications including 5 books on immunopharmacology, immunopathology and immunology of cancer.

Blogged on behalf of Milana Shapira and Sophia Doll

Dr Alex Kudrin considered the challenges of cancer vaccine development. Oncology is currently dominating many clinical pipelines and accounts for a majority of FDA approvals. Some cancer immunotherapies can be found on the market, but are not doing great from a commercial point of view. Often, as with Ipilimubab, pricing is high and therefore uptake is low. Making products more accessible, including to emerging markets, may be easier with off-shelf vaccines. Many players in the field are also small/mid-sized companies, which is limiting for development in terms of available resources. Thus, successful product development in the future will require more alliances and an integration between academia and industry.

Tell us your opinion on cancer vaccines below!

The presentations from the event will be made available from the 1st November.

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *